Free Trial
NASDAQ:ARVN

Arvinas (ARVN) Stock Price, News & Analysis

Arvinas logo
$6.29 +0.05 (+0.80%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$6.34 +0.05 (+0.81%)
As of 08/8/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Arvinas Stock (NASDAQ:ARVN)

Key Stats

Today's Range
$6.09
$6.29
50-Day Range
$6.24
$8.23
52-Week Range
$5.90
$29.61
Volume
2.12 million shs
Average Volume
2.07 million shs
Market Capitalization
$461.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.76
Consensus Rating
Moderate Buy

Company Overview

Arvinas Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

ARVN MarketRank™: 

Arvinas scored higher than 70% of companies evaluated by MarketBeat, and ranked 281st out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 12 buy ratings, 10 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Arvinas has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Arvinas' stock forecast and price target.
  • Earnings Growth

    Earnings for Arvinas are expected to grow in the coming year, from ($3.81) to ($3.68) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arvinas is -6.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arvinas is -6.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arvinas has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.65% of the outstanding shares of Arvinas have been sold short.
  • Short Interest Ratio / Days to Cover

    Arvinas has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Arvinas has recently increased by 9.37%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Arvinas does not currently pay a dividend.

  • Dividend Growth

    Arvinas does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.65% of the outstanding shares of Arvinas have been sold short.
  • Short Interest Ratio / Days to Cover

    Arvinas has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Arvinas has recently increased by 9.37%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Arvinas has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Arvinas this week, compared to 7 articles on an average week.
  • Search Interest

    6 people have searched for ARVN on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,377.00 in company stock.

  • Percentage Held by Insiders

    Only 4.73% of the stock of Arvinas is held by insiders.

  • Percentage Held by Institutions

    95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arvinas' insider trading history.
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Stock News Headlines

He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.
Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript
See More Headlines

ARVN Stock Analysis - Frequently Asked Questions

Arvinas' stock was trading at $19.17 on January 1st, 2025. Since then, ARVN stock has decreased by 67.2% and is now trading at $6.29.

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.03. The business's revenue for the quarter was down 70.7% on a year-over-year basis.
Read the conference call transcript
.

Arvinas (ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Arvinas' top institutional investors include Geode Capital Management LLC (2.17%), Acadian Asset Management LLC (1.96%), Monaco Asset Management SAM (1.23%) and Nordea Investment Management AB (0.59%). Insiders that own company stock include John G Houston, Sean A Cassidy, Andrew Saik, Ian Taylor, Noah Berkowitz, Ronald Peck and David K Loomis.
View institutional ownership trends
.

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arvinas investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/06/2025
Today
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARVN
CIK
1655759
Fax
N/A
Employees
420
Year Founded
N/A

Price Target and Rating

High Price Target
$55.00
Low Price Target
$8.00
Potential Upside/Downside
+214.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.55
Research Coverage
22 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.66)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$198.90 million
Net Margins
-19.47%
Pretax Margin
-19.42%
Return on Equity
-12.01%
Return on Assets
-6.97%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.64
Quick Ratio
4.58

Sales & Book Value

Annual Sales
$263.40 million
Price / Sales
1.75
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.30 per share
Price / Book
0.76

Miscellaneous

Outstanding Shares
73,420,000
Free Float
69,539,000
Market Cap
$461.81 million
Optionable
Optionable
Beta
2.22
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ARVN) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners